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The deterioration of human population due to an enhanced prevalence of infectious disease is 
becoming a global problem.  The rising dominance of multi-drug resistant microorganism is 
driving research efforts towards the discovery, design and development of newer 
antimicrobial agents.  As a contribution to these efforts, we synthesized compounds with 
same mechanism of action with available antimicrobial agents.  A series of eleven 
dihydropyrimidinoneswere synthesized byBiginelli condensation reaction with various 





C-NMR spectroscopy.  Discovery CEM microwave reactor was employed 
for the synthesis of some compounds to increase the yield.The compounds obtained were in 
high yields of 80 – 98%.  The synthesized compounds displayed low to moderate antifungal 
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1.1 Medicinal Chemistry 
Medicinal and pharmaceutical chemistry deals with the design, development and synthesis of 
drugs having therapeutic use and evaluation of their properties.  The discipline encompasses 
pharmacology, chemistry, more specifically organic chemistry and several other biological 
specialties. Medicinal chemistry aims at developing novel chemical entities that can be put to 
therapeutic use after systematic and thorough synthetic alteration.
1
  It involves identification 
of novel compounds and their chemical modifications so that the 
pharmacokinetic/pharmacodynamics properties and toxicological profiles are improved for 
human/animal administration.
2
Pharmaceutical chemistry primarily focuses on discovery of 
novel chemical entities of therapeutic value and quality control of medicinal formulations.
3
 
1.2 Drug design and discovery 
The primary objective of medicinal chemistry is the design and discovery of new compounds 
suitable for use as drugs.  The discovery of a new drug requires not only its design and 
synthesis but also to understand its mechanism of action against a desired target in the body 
and its suitability for use as a drug.
2
Drug discovery also requires fundamental research as 
well as knowledge of the diseased state at a molecular level. This and other aspects of drug 
design and discovery require input from specialists in other fields such as biologists, 
biochemists, pharmacologist, biophysicist, computation and medical scientists amongst 
others.
4
  A medicinal chemist should have an outline knowledge and understanding of these 
fields to design potent drugs.
3
 
Since ancient times a wide range of natural products have been used for medicinal purposes. 
These products, obtained from animal, vegetable and mineral sources, were sometimes very 
effective. However, many of the products were toxic and had severe side effects.
1
  
Information about these ancient remedies was not readily available to users until the 




  This invention led to the widespread 
publication and circulation of natural products and pharmacopoeias, resulting in a rapid 
increase in the use as well as misuse of drugs of natural product origin and other remedies. 





resulted in the progressive removal of preparations that were either ineffective or too toxic 
from herbals and pharmacopoeias. It also led to a more rational development of new drugs.  
Initially this development was centered on the natural products isolated from plant and 
animal material, but as knowledge increased a wider range of pharmaceutically active 
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compounds were used as the starting point for the development of drugs. The compounds 
onwhich a development is based are now known as lead compounds, while the synthetic 
compounds developed from a lead are referred to as its analogues.
5
 
The work of the medicinal chemist mainly focuses on the discovery of new lead compounds 
which has specific medical properties. This involves the development of more effective and 
safer analogues from both these new and existing lead compounds.This usually involves 
synthesizing and testing many hundreds of compounds before a suitable compound is 
produced.
3
The first rational development of synthetic drugs was carried out by Paul Ehrlich, 
who produced the antiprotozoal Arsphemamine1(also known as Salvarsan) in 1910, as shown 
in Figure 1.He combined synthesis with reliable biological screening and evaluation 
procedures.  Ehrlich, at the beginning of the 20
th
 century, had recognized that both the 
beneficial and toxic properties of a drug were important to its evaluation.  He realized that the 
more effective drugs showed a greater selectivity for the target microorganism than its host. 
Consequently, to compare the effectiveness of different compounds, he statedthat a drug’s 
selectivity was essential to improve the treatment of existing as well asnewly identified 




Figure 1. Structure of Salvarsan 
1.3 Microbial infections 
Healthy human beings live normally with microbial flora. There are approximately ten times 
bacterial cells in the human flora than the normal human cells in the body, with large number 
of bacteria’s on the skin and as gut flora.
6
Normal flora can be pathogenic or nonpathogenic. 
Nonpathogenic microbes protect its host from invasion of pathogens into the human body.
7
 
Pathogenic normal flora have pathogenic effects if they are found at a site where they are not 
normally found e.g. bacteriods, normally found in intestines, can lead to production of 
abscess if they penetrate into a traumatic wound or surgical wound.  E. coli have positive 
effects in gastrointestinal tract,but they also show negative effect, causing urinary tract 
CHAPTER I: INTRODUCTION   
3 
 




1.3.1 Bacterial Infection 
Bacteria are single-celled organisms which populate almost every niche on earth, from the 
hottest springs and chilliest waters to many spaces on and within the human body.  As a 
group they are extremely diverse in size, shape, motility, nutrient requirements and 
pathogenicity (ability to cause disease), but share the common trait of lacking a true nucleus 
and hence are  referred to as “prokaryotic”.
9
 
Bacteria are classified as Gram-negative and Gram-positive.The bacterial cell wall of Gram-
positive consists of peptidoglycan and techoic acid. Gram negative bacterial cell wall consists 
of peptidoglycan, lipoprotein, lipopolysaccharides, phospholipids and proteins.
10
The major 
site of action of antimicrobials is on peptidoglycan which is one of the components of the cell 
wall.This layer is essential for the bacteria to survive in hypotonic environments. Loss or 
damage of this layer leads to destruction of the rigidity of the bacterial cell wall resulting in 
death.  Antimicrobial agents easily pass through the outer cell wall of gram positive bacteria 













Figure 2.Structure of bacteria
9
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Though most of the earliest bacteria discovered were pathogens (disease-causing organisms) 
however a vast majority of bacteria on earth are harmless or even beneficial to humans.  
Many animals rely on gut bacteria to provide nutrients from food, which we are unable to 
synthesize ourselves (for example, E. coli in the gut produce Vitamin K).
11
Additionally, 
commensal (non-pathogenic) bacteria fill niches in our body and use resources that would 
otherwise be available to other pathogenic microorganisms.  For instance, our skin and oral 
cavity are covered with bacteria, most of which will never harm us, as they live in a delicate 
balance with our immune system.
12
However pathogenic bacteria can cause disease in humans 
and animals as shown in Table 1. Some examples of pathogenic bacteria are:  
Staphylococcus aureus, Pseudomonas aeruginosa and Mycobacterium tuberculosis. 
Table 1.An overview of bacterial infections
13
 
Name of microorganism species Site of body affected Microbial infections caused 
Streptococcus  pneumoniae 
Haemophilus influenza 
Brain Bacterial meningitis 




Lungs Respiratory tract infections 
Staphylococcus aureus 
Pseudomonusaeruginosa 
Skin Skin infections 
Neisseria gonorrhea 
Treponemapallidum 




Urinary System Urinary tract infections 
Streptococcus pyogenes 
Haemophilus influenza 
Respiratory system Respiratory tract infections 
Staphylococcus aureus 
Neiserriagonorrhoea 
Eyes Eye infections 
Fungi can also cause superficial, systemic and opportunistic infections such as candida 
infection, fungal meningitis and Pneumocystis pneumonia.
14
Majority of the harmful 
microorganisms that a human body comes across are rendered harmless by the protective 
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effects of the body’s immune system
7
.However, some resistant species are pathogenic and 
can cause infectious diseases such as tuberculosis and typhoid,which are difficult to treat and 
need attention by medicinal chemists. 
1.3.2 Fungal Infections 
Fungi are eukaryotic (as shown in Figure 3)and include organisms such as molds and yeasts. 
Approximately 100 fungal species (out of ~100,000 known) are pathogenic.
15
Yeasts are 
unicellular and generally divide by simple binary fission (one cell divides into two).Molds, 




Figure 3.Structure of fungi
17
 
Fungi life cycle pass through both an asexual and a sexual stage. They exist as multicellular 
organisms during much of this period and at this point are far from being “micro” 
organisms.
18
Nevertheless, because it is often their (microscopic) spores which are responsible 
for diseases, they remain classed as general “microbes”.  Diseases caused by fungi can be 
classified according to the parts of the body affected by the fungi, as depicted in the Table 2. 
Diseases due to fungi can also be caused by contact with or ingestion of toxins produced by 
certain species.  For example, aflatoxin is a poison produced by the mold Aspergillusflavus, 
when ingested; symptoms may induce vomiting, convulsions or death.
20
  In 1928, Alexander 




Table 2.Some examples of superficial fungal infection
18
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Classification Affected Site Notes 
Tineapedis 
(Athletes Foot) 
Feet The most common fungal infection. Initial 
infection can be dry and scaly, however 
secondary bacterial infection and accumulation 
of soggy debris can commonly occur.
19
 
Tineacapitis Scalp More common in Children. Infected hair can 
break leaving a bald area.
19
 
Tineabarbae Beard Common among men that work with animals 
e.g. agricultural workers due to animal human 
transmission. May be accompanied by bacterial 





Skin other than 
bearded area, 
scalp, groin, hands 
or feet 
Tends to present as irregular expanding rings 






and perianal areas 
Lesion may be on the inner thighs, pubic, 
inguinal region or scrotum. Yeast infections 
(usually Candida albicans) are also commonly 
found in these areas.
18
 
1.4 Antimicrobial agents 
Antimicrobial came from Greek words which are anti, mikros and bios.  Here Anti means 
against, mikrosindicated little, and bios means life.
22
Antimicrobial is the term used for all the 









They have been used for 
treatment in humans and animals. Antimicrobials have also been used prophylactically to 
avoid diseases and in food production.The term antimicrobial agent can also be used to 
designate synthetic as well as naturally obtained drugs that attenuate microorganisms.
13
 
The chemicals used to treat infectious diseases fall into two main categories, namely natural 
products and chemotherapeutic agents.
26
Natural products are secondary metabolites that are 
only generated by certain microorganisms and are usually large, elaborated organic molecules 
that require complex enzymatic synthesis.
27
Alternately chemotherapeutic agents comprise of 
compounds that have been synthesized chemically. A hybrid of these two categories exists, in 
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which natural products that have been chemically modified to alter particular characteristics 
and is referred to as semi-synthetic antimicrobials.Antimicrobials are also classified 




1.4.1 Classification of antimicrobials 
1.4.1.1 Classification according to spectrum of activity: 
Depending on the range of bacterial species susceptible to these agents, antibacterials are 
classified as broad-spectrum, intermediate-spectrum or narrow- spectrum.
28
  Some examples 
are shown inFigure 4. 
• Broad spectrum antibacterials are active against both Gram-positive and Gram-
negative organisms.  Examples include: tetracyclines, phenicols, fluoroquinolones, 
“third-generation” and “fourth-generation” cephalosporin.
29
    
• Narrow spectrum antibacterials have limited activity and are primarily only useful 
against particular species of microorganisms.  For example, glycopeptides and 
bacitracin are only effective against Gram-positive bacteria, whereas polymixins are 
usually only effective against Gram negative bacteria.  Aminoglycosides and 
sulfonamides are only effective against aerobic organisms, while nitroimidazoles are 
generally only effective for anaerobes.
28
 
1.4.1.2 Classification based on effect on microorganism: 
• Bactericidal drugs are those that kill target organisms.  Examples of bactericidal drugs 
include, penicillins2, fluoroquinolones3and cephalosporins4.
30
 
• Bacteriostatic drugs inhibit or delay bacterial growth and replication.  Examples of 
such include tetracyclines5 and sulphonamides9.
31
  
• Some antibiotics can be both bacteriostatic and bactericidal, depending on the dose, 








Figure 4.Examples of antimicrobial agents based on their classification 
Numerous antimicrobial agents are known, however, not all of them can be used in vivoas in 
addition to their antimicrobial activity they can be toxic to human beings.
33
Antimicrobials 
have to be non-toxic, non-allergenic, effective and selective, chemically stable, active against 
possibly more than one bacterium and inexpensive.  The ratio between the therapeutic effect 
and the toxic effect in the human body is described by the drugs therapeutic index (TI).  
Antimicrobial drugs can have several different modes of action.
18
Penicillins2 and 
cephalosporin4act by interfering with the synthesis of cell wall, while tetracyclines5 act by 




1.5 History and Development of Antimicrobial Agents 
Looking back on the history of human diseases, infectious diseases have accounted for a very 
large proportion of diseases as a whole. It was not until the latter half of the 19
th
century that 
microorganisms were found to be responsible for a variety of infectious diseases that had 
been plaguing humanity from ancient days.Accordingly, chemotherapy aimed at the causative 
organisms was developed as the main therapeutic strategy.
34
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The first antimicrobial agent discovered was Salvarsan1, a remedy for syphilis that was 
synthesized by Ehrlichin 1910.
5
In 1935, sulfonamides 9(Figure 5) were developed by 
Domagk and other researchers.
35
These drugs were synthetic compounds and had limitations 












Figure 5. Structure of Sulphonamide 
In 1928, Fleming discovered penicillin.  He observed that the growth of Staphylococcus 
aureus was inhibited in a zone surrounding a contaminated blue mold (a fungus from the 
Penicillium genus) in culture dishes, leading to the finding that a microorganism could 
produce substances that might inhibit the growth of other microorganisms. This antibiotic 
was named penicillin and it came into clinical use in the 1940s.  Penicillin, which is an 
outstanding agent in terms of safety and efficacy, lead the era of antimicrobial chemotherapy 
by saving lives of many wounded soldiers during world war II.
21
 In subsequent decades new 
classes of potent antimicrobial agents were developed, leading to a golden age of 
antimicrobial chemotherapy, as depicted in Figure 6. 
 




Figure 6.Development of penicillin 
In 1944, streptomycin 6, an aminoglycoside antibiotic, was obtained from the soil containing 
bacterium Streptomyces griseus.
36, 37
Thereafter, chloramphenicol 8, tetracycline 5 and 
glycopeptide e.g. Vancomycin14(Figure 7) was discovered from soil bacteria.  The 









Figure 7. Structure of Vancomycin 
Improvements in each class of antimicrobial agents continued to achieve a broader 
antimicrobial spectrum and higher antimicrobial activity. For example, in case of β-lactam 
antibiotics (penicillins, cephems, carbapenems and monobactams); penicillins were originally 
effective for Gram-positive organisms such as S. aureus.  Later, to address penicillin-resistant 
S. aureus which produces the penicillin hydrolyzing enzyme penicillinase, methicillin was 
developed.
38
On the other hand, attempts to expand the antimicrobial spectrum yielded 
ampicillin, which is also effective against Gram-negative Enterobacteriaceaeand piperacillin 
as well as against Pseudomonas aeruginosa. 
Cephems were developed in the 1960s, and came into widespread use.Cephems are 
classifiedinto several generations according to their antimicrobial spectra. First-generation 
e.g. cefazolin15(Figure 8),are effective only for Gram-positive organisms and Escherichia 
coli, although their antimicrobial activity against these organisms is potent.  
 
 
Figure 8. Structure of Cefazolin 
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Second-generation cephems e.g. cefotiam16(Figure 9)have an extended antimicrobial 





Figure 9. Structure of Cefotiam 
Third-generation cephems e.g. Cefotaxime17have higher efficacy for Gram-negative 
organisms and some drugs of this generation are also effective for P. aeruginosa, although 
the antimicrobial activity against Gram-positive organisms is generally lower than that of the 
first generation.  These drugs are effective not only for Gram-positive and Gram-negative 
bacteria but also anaerobes and their antimicrobial activity is strong.  The monobactam 
antibiotic aztreonam18 exerts an antimicrobial effect only on Gram-negative bacteria.
39
  The 
structures of compounds 17 and 18 are depicted in Figure 10. 
 
 
Figure 10. Structure of some of the third generation cephalosporin 
1.6 Mode of action of antimicrobials 
Antimicrobial agents act by altering the cell wall synthesis, ribosomal function, folate 
synthesis, nucleic acid synthesis and plasma membrane integrity as indicated in Table 3.
40
 
• Inhibition of cell metabolism 
Antibacterial agents which inhibit cell metabolism are called antimetabolites. These 
compounds inhibit the metabolism of a microorganism, but not the metabolism of the host. 
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They do this by inhibiting an enzyme catalyzed reaction which is present in the bacterial cell, 
but not in animal cells. The best known examples of antibacterial agents acting in this way 
are the sulfonamides. 
• Inhibition of bacterial cell wall synthesis 
Inhibition of cell wall synthesis leads to bacterial cell lysis (bursting) and death.  Agents 
operating in this way include penicillins and cephalosporins. Since animal cells do not have a 
cell wall, they are unaffected by such agents e.g. penicillin 2. 
• Interactions with the plasma membrane 
Some antibacterial agents interact with the plasma membrane of bacterial cells to affect 
membrane permeability. This has fatal results for the cell e.g.  Polymyxins B, depicted in 
Figure 1, operate in this way. 
 
Figure 11. Structure of Polymixin B 
• Disruption of protein synthesis 
Disruption of protein synthesis means that essential enzymes required for the cell's survival 
can no longer be made. Agents which disrupt protein synthesis include the Tetracycline 5 and 
Chloramphenicol 8. 
• Inhibition of nucleic acid transcription and replication 
Inhibition of nucleic acid function prevents cell division and/or the synthesis of essential 
enzymes. Agents acting in this way include Proflavin20, as depicted in Figure 12. 
 
Figure 12. Structure of Proflavin 
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Table 3.Mode of antimicrobial actions
18
 
Mode of action Drugs 
Cell membrane • polymixin 
• bacitracin 
• colistin 




DNA replication • quinolones 
DNA –dependent RNA polymerase • rifampicin 
Folic Acid metabolism • trimethoprim 
• ormetoprim 
• sulphonamides 
Protein synthesis 30S Ribosome 
• tetracycline 
• aminoglycosides 




When bacterial cells multiply and divide they make new molecules of DNA, RNA and 
protein. From their environment they obtain smaller units of amino acids and sugars which 
are found on their cell walls and cell membrane.  Antimicrobial agents act on specific 
targets,which is the basis of their antimicrobial action.
13
 
1.7 Mode of antimicrobial resistance  
There are basic mechanisms by which microorganisms can be resistant to antimicrobial 
agents. These cases of acquired resistance are of greater concern, where initially a number of 
susceptible bacteria become unresponsive to an antibacterial agents and spreads under the 
selective pressure of use of that agent, as shown in Figure 13. 
These mechanisms are: 
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• Development of altered receptors for a drug. 
• Decrease in the amount of drugs that reach the receptor by altering bacterial cell wall 
that no longer contain the binding site of antimicrobial agent or increase in removal of 
the drug by efflux pumps. 
• Inactivation of the drug. 
• Synthesis of resistant metabolic pathways. 
• Organism possess enzymes that destroy the antibacterial agent before it can have an 
effect e.g. β-lactamases. 




Usually the bacteria can possess one or all of these mechanisms.While antibiotics are 
effective against majority of infections, there is also an increase in resistance by some 
pathogens. This threatens to undermine few remaining drugs on market that are still effective 
against them.  
 
Figure 13.Mode of antimicrobial resistance.
42
 
The ability of the bacteria to establish new mutant variants against man made antibiotics 
means antibiotic resistance will remain a threat for many coming decades.  However there is 
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1.8 Need for development of antimicrobial agents 
The remarkable success of antimicrobial drugs generated a misconception in the late 1960s 
and early 1970s that infectious diseases had been conquered.  However, 40 years later, 
infectious diseases remain the second-leading cause of death worldwide.  Furthermore, the 
emergence of multidrug-resistant bacteria has created a situation in which there are few or no 
treatment options for infections with certain microorganisms.
44
The threat of bioterrorism, 
which gained widespread public attention after 11 September 2001, has expanded the 
problem because genetic changes in pathogens could render them resistant to currently 
available antimicrobials.
45
  Pattern in rates of death from infectious disease in the 20
th
 century 
(from 1900 to 1980) revealed that the rate has dropped from 797 per 100,000 people to 36 per 
100,000 people, a reduction by a factor of more than 20 and a testament in part to the efficacy 
of antibiotics(Figure 14).However, from 1980 to 2000, that rate doubled, largely because of 
HIV but also due to the spread of drug-resistant bacterial pathogens, such as Methicillin-
resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococci, multiple-drug-




Figure 14.Trends in developments of antimicrobial agents 
While the rise in mortality is due partly to infection in more seriously ill or immuno-
compromised patients, there is no doubt for the need for new strategies and new molecules to 
treat pathogens that are resistant to nearly the full range of contemporary antibiotics.  We are 
at a critical point at which infections caused by some bacterial pathogens are untreatable. The 
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need for new antimicrobial agents is greater than ever because of the emergence of multidrug 
resistance in common pathogens, the rapid emergence of new infections, and the potential for 
use of multidrug-resistant agents.  Unexpectedly, some pharmaceutical companies have 
indicated that they are limiting anti-infective research programs.  Despite the critical need for 
new antimicrobial agents, the development of these agents is declining. Solutions 
encouraging and facilitating the development of new antimicrobial agents are needed. 
1.9 Synthesis of Dihydropyrimidinones 
1.9.1 Introduction dihydropyrimidine 
Diverse Biginelli products by structural manipulation have shown various biological 














Dihydropyrimidinones, aBiginelli productis an important class of medicinal scaffold and 
found as structural component of many biologically active drugs in market.  Hence the 
development of efficient and general synthetic methods for construction of 
dihydropyrimidinones is an important research challenge with high applicability in 
pharmaceutical industry.  Figure 15shows some of dihydropyrimidinones i.e. 
felodipine21and nifedipine23. 
 
Figure 15.Structure of Dihydropyrimidinones 
Monastrol was the first drug congener of dihydropyrimidines class synthesized by Biginelli 
reaction with significant anticancer activity. Monastrol has ester functional in its structural 
scaffold. During an attempt in anticancer research another dihydropyrimidine withfuryl 
substitution was synthesized and was found to be more potent than monastrol.  
Chemistry of dihydropyrimidines is recorded long back in the history. Dihydropyrimidines 
are of great interest for Pharmaceutical Chemistry. Heterocycles that consists of 
dihydropyrimidinepharmacophore are reported to exhibit antihypertensive, anti-HIV, 
antitumor, antiepileptic, antimalarial, antimicrobial, anti-inflammatory, antitubercular and 
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antibacterial activity.  Over the years, much attention was given for the synthesis of 
dihydropyrimidines.  Nowadays the emphasis has been put on understanding the course of 
reaction with more emphasis on structural variants.  Different methods for the synthesis of 
dihydropyrimidines are explained below in brief.  Present work deals with exploration of 
Biginelli’s reaction for development of heterocyclic motifs with antimicrobial potential 
activity. 
1.9.2 Synthesis: Biginelli condensation reaction 
Historically the first reaction was reported by Pietro Biginelli from University of 
Florence
40
(1893).Biginelli did the reaction as acid catalyzed condensation of ethyl 
acetoacetate, benzaldehyde and urea in ethanol. The mixture was refluxed and on cooling he 
obtained a product that was solid crystals and the product was 3,4-dihydropyrimine-2(1H)-
one
43




Scheme 1. The acid catalyzed formation of 3, 4- dihydropyrimine-2(1H)-one (26) 
Hydrochloric acid was the acid used and the reaction was called Biginelli condensation 
reaction. In the early part of the 20
th
 century Biginelli's work was ignored.  The work 
remained unexplored for some time.  Interest started increasing around 1970s and 1980s and 
it was eventually extended by alteration of all the three building blocks. 
Folkerset al. made the first attempt to research and understand Biginelli’s reaction in 1933.  
The reaction was done under acidic condition. They could prove intermediate 1,1-
(phenylmethanediyl)-di-urea, as depicted in Figure 16,to transform to end product of 
Biginelli compound.
51
After few decades Sweet and Fissekis (1973) reinvestigated the same 
reaction.
51
They came up with a mechanism that opposed Folkers suggestion. 
 
  




Figure 16.Structure of Intermediates compounds by Folkers and Johnson 
1.9.3 Knoevenagel condensation and reaction with urea (2-step reaction) 
Atwal and O’Reilly et al (in 1987) did a two-step process and reported troubles associated 
with Biginelli compounds. There was a poor yield, with aliphatic aldehydes and aldehydes 
having hindered carbonyl function withortho substituents. The first step was about synthesis 
of unsaturated carbonyl compound by Knoevenagel condensation.
50
The second step was base 
catalyzed addition of substituted ureas, as depicted below. 
 
Scheme 2.The base catalyzed formation of dihydropyrimidines  
The modified Biginelli reaction was not exploring much since it involves two steps. Kappe 
(1997)
52





C NMR.  According to his mechanism shown below the first step evidently 
involved nucleophilic attack of urea.  The nucleophilic attack was on the electron deficient 
carbon of aldehyde function. It was an acid catalyzed reaction that resulted in the formation 
of N-acyliminium ion as the precursor from an aldehyde and urea compound.  The second 
step was addition of a pi nucleophile i.e. methylene adding onto the intermediate.  He 
concluded that dihydropyrimidines were formed in small quantities.
43, 53-61
 




Scheme 3.Synthesis of 3,4-dihydropyrimidinone through N-acyliminium ion 
Saloutina and coworkers replaced acetoacetic ester with CF3COCH2CO2Et. They isolated 
intermediate on the scheme. The next step was dehydration using p-toluene sulphonic acid.  
The dehydration part in this mechanism was also investigated using GaCl3 as Lewis Acid.  
They found out that anhydrous GaCl3 gives high yields as compared to hydrated GaCl3.  
Hydrated GaCl3 does not perform well in the reaction. 
1.9.4 Reaction with antimonytrichloride as a catalyst 
In 2007 Cepenacet al
62
 used a different catalyst antimonytrichloride, which was a Lewis acid 
catalyst.  The reaction was found under that condition that proceeds via intermediate 41, 
which was different as proposed by Kappeet al. with iminium formation, as depicted in 
Scheme 4. 
 
Scheme 4.Synthesis of 3, 4-dihydropyrimidinone through 3-ureido-crotonates 
Antimony (III) Chloride was found to be very efficient and the reaction proceeds with good 
to high yields. Although it’s not an ideal catalyst, it promoted preparation to sterically 
hindered dihydropyrimidines. 
1.9.5 DFT Study  
In 2008 Jian–Hua Zhou (DFT study) investigated the procedure described by Biginelli, which 
is condensation of urea, benzaldehyde and ethylacetoacetate under classical reaction 
conditions. According to Kappe’s mechanism, five intermediate structures were optimized 




CHAPTER I: INTRODUCTION   
21 
 
In 2009 De Souz d et aldid some mechanistic investigations of Biginelli reaction.
64
They 
supported Fokker’s and Johnson’s proposal and their conclusion was based on density 
functional theory calculations (DFT). Mass spectrometer with accessories for various 
ionizations was used whereas DFT calculations was used to investigate the Biginelli’s 
proposed major competing mechanism.
64
 
1.9.6 Reaction with Nickel (II) nitrate hexahydrate as a catalyst  
Boumoudet al also reported their investigations using nickel (II) nitrate hexahydrate as 
catalyst. They supported Folker’s mechanism.  Most of the investigations were on the use of 
the Lewis acidand Lewis acid like catalysts and few papers which described the use of basic 
catalysts. Chinese researchers recently came up with the use of strong bases and also 
proposed a different pathway, as depicted in Scheme 5.The reaction proceeded well in the 
presence of Bronsted base and they obtained moderate to good yield.  Enone and bisurea 





Scheme 5.The base catalyzed formation of 3,4-dihydropyrimidinone (11) 
The above mentioned mechanisms and processes re-investigations with catalysts were found 
to be perspective trend in the course of Biginelli reaction as compared to what have been 
reported earlier on motto that reaction seemed to follow Kappe Mechanism.  There is another 
mechanism report using hexaaqua-Al (III)BF4 
66
 as a mild acid catalyst. 
1.10 Biological activity of dihydropyrimidinones 
1.10.1 Antihypertensive  
Some biologists found Biginelli products resembling with that of Hantzsh’s 1,4-
dihydropyridine. These were the side products of Biginelli reaction in the initial experiment 
such as the aza- analogues of Nifedipine47 and other known compounds which are calcium 
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channel modulators. Biginelli compounds are promising structural targets for bringing them 
to medicinal use. Figure 17 depicted below showing some resemblance between Biginelli 















Figure 17.Biginelli’s product 46 and antihypertensive compounds47 
Figure 18 displayssomeorally effective antihypertensive agents. Hetero-substituted 
dihydroxypyrimidine (DHPM) shown below with branched ester and an alkyl-thio- group like 
S-Me, was found to have optimal antihypertensive activity. 
 
Figure 18.Antihypertensive compounds 
1.10.2 Potassium channel antagonists  
The compound shown in Figure 19 was annulation of benzamidole ring with Biginelli 









Figure 19.Potential Potassium antagonist 
1.10.3 Anti-HIV  
Batzelladine and its derivatives of DHPMs were obtained from marine natural source.  They 
have promising anti-HIV activity.  Batzelladine’s low molecular weight derivatives were 
found to inhibit the HIV virus by binding to gp-120 to CD4 cells.
47
Figure 20 displays the 
structure of BatzelladineA51. 
 
Figure 20.Structure ofBatzelladine A 
1.10.4 Antitumor 
Monastrol is the first Biginelli compound which has very good anticancer activity.  Some 
compounds have also been investigated for their action as kinesin Eg5 inhibitors.  Furyl 
derivatives 53 were also discovered during this attempt and it was found to be more potent 




Figure 21.Monastrol52 and potential anticancer compounds53 
Some of the reported Eg5 inhibitors were Enastron, Dimethylenastron and 
Fluostrastrol.
48
Monastrol’s52.Thepotency was compared to these new inhibitors and they 
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were found to have a better fit of the ligand at the allosteric binding site.  Some 
pyrimidinone-peptide hybrid molecules were also identified as Hsp70 modulators that inhibit 
cell proliferation. 
1.10.5 Antiepileptic  
Phenobarbital is the drug of choice of epilepsy.  Biginelli’s compounds have a structural 
similarity with Phenobarbital.  The compounds,shown in Figure 22, were investigated for 




Figure 22.Structure of Phenobarbital54and potential antiepileptic compounds55 
1.10.6 Antimalarial  
Other pyrimidine-amides derivatives of DHPMs are new class. They belong to Hsp 70 
modulators.  Nine compounds are under clinical investigation against antimalarial activity 
because they inhibited the replication of pathogenic P. falciparum.
24
  The structure of 
thepotential antimalarial compound is shown in Figure 23. 
 
Figure 23.Structure of potential antimalarial compounds 
1.10.7 Anti-microbial  
1-aryl-4-methyl-3,6-bis(5-methylisoxazol-3-yl)-2-thioxo-2,3,6,10b-tetrahydro-1H 
pyrimido[5,4-c]quinolin-5-ones, which was a Biginelli product,  has shown potent 
antimicrobial activity such as  antibacterial, antifungal and antimalarial activities.
24
 




Figure 24.Structure of potential antimicrobial compounds 
1.10.8 Anti-inflammatory  
3-(4,6-disubstituted-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-propionic acid derivatives 
were screened and showed anti-inflammatory activity by rat paw edema method. Further 
some of the substituted Biginelli compounds in this series with cyanide and ester 
functionalities were found to have promising antibacterial agents.
49, 71
Figure 25 depicts 
structures of two potential anti-inflammatory compounds. 
 
Figure 25.Structure of potential anti-inflammatory compounds 
1.10.9 Antitubercular agents 
Dihydropyrimidines were found to have antitubercular activity against Mycobacterium 





 (as shown in Figure 26)were found to be more potent and more active  than 
isoniazid. 




Figure 26.Potential antitubercular compounds 
1.10.10 Antibacterial  
Substituted Biginelli compounds (Figure 27)were found to exhibit promising antibacterial 
activity.  This includes some ester and cyanide as depicted below.
23, 25, 46, 74
 
 
Figure 27.Potential antibacterial compounds 
1.10.11 Antioxidants and antifilarial 





Figure 28.Potential Antioxidants and antifilarial compounds 
1.10.12α-1A adrenergic receptor antagonists 








Figure 29.Potential antiadrenergic compounds 




Figure 30.Potential anti HBV compounds 
1.11   Characterization of dihydropyrimidinones 
The principal tools used for the characterization of dihydropyrimidines were Nuclear 
Magnetic Resonance (NMR) Spectroscopy and Infra-red spectroscopy (IR).Confirmation of 
dihydropyrimidines structure was done by spectroscopic techniques such as 
1
H NMR and 
13
C 
NMR. Fromliterature, the presence of a characteristic singlet peak in 
1
H NMR at 2.36 ppm 
corresponds to the CH3 of the pyrimidine. A singlet peakresonating  around 8.54 ppm  was 




CNMR spectra of 
dihydropyrimidine, the carbon signals (C2, C3, C5, and C6)appeared at δ166.3, 144.9, 159, 
and 17.9 respectively.  Different functional groups of synthesised compounds were 
determined using Infra-red spectroscopy.  The presence of the characteristic band around 
3100-3300cm
-1
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1.12 Rationale and motivation 
Currently due to various factors (resistance, misuse/abuse of drugs and other environmental 
factors) infections caused by some bacterial and fungal pathogens are untreatable.  The need 
for development of new antimicrobial agents is more than ever because of the emergence of 
multidrug resistance in common pathogens, the rapid emergence of new infections, and the 
potential for use of multidrug-resistant agents.  In spite the urgent need for new antimicrobial 
agents, the development of these agents is declining.  Solutions encouraging and facilitating 
the development of new antimicrobial agents are needed.  It is well documented as mentioned 
earlier thatBiginelli products have shown diverse biological activities such as anti-tubercular, 
antiviral, antitumor, antifungal, anti-proliferative, anti-inflammatory and antibacterial 
activity.  Dihydropyrimidinones, aBiginelli productis an important class of privileged 
medicinal scaffold and found as structural component of many biologically active drugs in 
market including antibacterial and antifungals.  These observations have motivated us to 
synthesize some analogs of dihydropyrimidinones by using Biginelli reaction conditions and 
evaluate them for potential antibacterial and antifungal activities. 
1.13Research aims and objectives  
• To design the scheme for synthesis of proposed compounds  
• To synthesize the title compounds by an proposed method 
• To carry out the required confirmatory test such as TLC for monitoring/completion of 
the reaction. 
• To confirm the structures of the synthesized compounds by IR, 1HNMR and Mass 
spectroscopy. 
• To evaluate the proposed compounds for their antimicrobial activity. 
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2.1 General Procedure 
The synthesized compounds were identified and characterized using the following methods: 
• Melting point determination 
• Thin Layer Chromatography 
• Nuclear Magnetic Resonance Spectroscopy (NMR). 
This was done to show that all prepared compounds were of different nature than the starting 
material.  Melting point determination was carried out in closed capillaries using 




C were all recorded using a 
Bruker Advanced III 400MHz spectrometer.  All the spectras were all recorded at room 
temperature.  The chemical shifts were recorded in deuterated chloroform (CDCl3) against 
the internal standard of trimethylsilane. The reactions were all monitored by using TLC Thin 
Layer Chromatography on MERCK 0.25 SILICA GEL (60F254) and were visualized with UV 
light.  Perkin Elmer spectrum 100 FT-IR spectrophotometer was used to record IR spectra. 
2.2 Synthesis of dihydropyrimidinones 
In a 100 ml round bottomed flask, benzaldehyde (10mmol, 1g) was 
added.Ethylacetoacetate(10 mmol) and urea (12mmol) was also added into the same 50ml 
round bottomed flask .CuCl2.2H2O was used as a catalyst. The mixture was stirred rapidly 




C for 3 hrs in the absence of a solvent. Cupric chloride and urea 
dissolved after some few minutes and the solid mixture changed to oily after about 20mins. 
After 30mins of gradual stirring the oily mixture changed to solid.  Stirring was continued for 
the remaining 2hrs 30mins. TLC was used to monitor the reaction.  After 3hrs elapsed the 
reaction was cooled at room temperature.  Ice was added to the solid mixture and crushed 
until separated solid particles were obtained.  The separated solid particles were filtered and 
checked using TLC for purity. If not pure the solid particles were purified by crystallization 
whereby the particles were dissolved in a beaker of 20ml ethanol and heated until 5ml 
ethanol remained.  The mixture was left to crystallize.  The same process was successfully 
applied to structurally varied aldehydes to yield 3,4-dihydropyrimidine-2(1H)-ones as 
depicted inScheme 6and Table 4below.
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70 71 72 73
R1 = C4H9, C7H80, C6H5Cl, C6H5F. C6H5Cl, C6H5Cl, C8H10O2, C7H8O, C8H10O2, C6H6
R2 = C2H5
 
Scheme 6. Overall Procedure of the synthesized dihydropyrimidinones compounds 
Table 4. Dihydropyrimidines derivatives 
Serial number -R1 -R2 





3c   
C2H5 
3d   
C2H5 
3e   
C2H5 






















Some of the compounds were synthesized using microwave reactor.  Absolute ethanol was 








2.3 In vitro antimicrobial activity 
The dihydropyrimidinones (3a-3k) were further assessed for antimicrobial activity against 




2.3.1 Microorganism used 
Standard cultures of two gram +ve [Staphylococcus aureusATCC25923, Bacillus 
subtilisATCC6051], two gram -ve [Escherichia coli ATCC35218, Pseudomonas aeruginosa 
ATCC27853], three fungal strains [Candida albicansATCC90028, Cryptococcus 
neoformansATCC66031 and AspergillusnigerATCC16404]were used for the antibacterial 
and antifungal activity respectively.  Culturing and subculturing (one day prior to testing) of 
these microorganisms was carried out at the department of microbiology, Inkosi Albert 
Luthuli hospital, Durban, South Africa.  Subculturing of these microorganisms was used in 
this assay. 
2.3.2 Preparation of medium 
The nutrient medium was prepared by dissolving 22 g of Muller-Hinton Broth containing 
acid hydrolysate of casein, beef extract and starch in 1 L of double distilled water. The pH of 
this medium was adjusted to 7.4 ± 0.1 and sterilized by autoclave for 15 min at 121°C. The 
solution was allowed to cool and stored at a temp of 4°C. Sterility check was performed by 
incubating un-inoculated media in an aerobic incubator at 37 °C for 18-24 h. For antifungal 
activity, RPMI 1640 medium with L-glutamine and 0.165 M MOPS and without sodium 
bicarbonate (Lonza) was used. 
2.3.3 Preparation of test compounds (stock solution and working standard) 
An accurately weighed quantity (4.000 mg) of the synthesized compounds and standard drugs 
were dissolved in 1 ml of DMSO to give stock solution (4000 µg/mL).  Further, 100µl of 
stock solution was diluted with 900 µl of double distilled water to afford working standard 
solution (400 µg/mL). 
2.3.4 Preparation of inoculum 
One day prior to testing one or more identical colonies of microorganisms were suspended 
in4.5 ml sterile double distilled water.  The inoculates were adjusted to 0.5 McFarland 
standard (1.5 X 108 cfu/mL).  A density check turbidmeter was used to ensure that the 
inoculum was a 0.5 McFarland standard. 
2.3.5 Broth micro-dilution method 
The preliminary in vitro antimicrobial activity for the newly synthesized title compounds (3a 
to 3k) was evaluated using the broth micro-dilution method.
83, 84
100 µl of sterile 




doubledistilled water was added to all outer-perimeter wells of a 96-well microliter plates 
tominimize evaporation of the medium in the test wells during incubation.  To the 
remainingtest wells 100 µl of MHB was added.  Two fold serial dilutions of the test 
compounds andstandard drugs (amoxicillin and Amphotericin B) were made directly on the 
microplate usingMHB.  The compounds were tested at final concentration of (200, 100, 50, 
25, 12.5, 6.25, 3.125,1.56, 0.78, 0.39 µg/ml). Finally, 10 µl of the freshly prepared bacterial 
or fungal inoculumwas added to the wells.  The microliter plates were covered and sealed 
with parafilm andincubated at 37 ± 1 
0
C for 24 h. After this, 10 µl of freshly prepared 
resazurin (0.4 mg/ml)was added to the test wells and incubated further for 5h. MIC was 
determined as a bluecolour in the test well was interpreted as no bacterial growth and a pink 
colour was scored asgrowth.  The MIC was thus defined at the lowest drug concentration that 
prevented a colourchange from blue to pink.  This experiment was conducted in duplicate and 
the average MICvalues in µg/ml. 
References  
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 microbiology2005, 43, 5243. 
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3 Results and discussion 
Eleven compounds were successfully synthesized using Biginelli condensation reaction.  It 
was a one-step reaction.  All products were substituted at 1,2,3,4 positions of the heterocyclic 
ring with positions 1, 2, 3 being the same for all compounds with NH group on carbon 1 and 
2 and S group on carbon 3.  An ester was found at position 5 and a methyl group at position 
6. 
3.1 Chemistry  
3.1.1 Synthetic data 
During the reaction there is a formation of N-acyliminium79 after thiourea 75 and 
benzaldehyde76 have been mixed.  This is through an unobserved (
1
HNMR) hemiaminal77. 
Combination of an enol tautomer of ethylacetoacetate leads to the formation of 
dihydropyrimidine80as a precursor.  The rate limiting step is the first step that leads to the 
formation of 79, hence preventing 77 and 78 from being observed on NMR. 
 
Scheme7.The mechanistic pathway for the formation of dihydropyrimidines 
3.1.2 Physical properties 
Generally all the compounds appeared orange, yellow and light yellow solids.  The yields 
were between 85-95% for all compounds synthesized.  The melting points were between 135 
and 221
0
C. The data is summarized in Table 5. 
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   Table 5.Physical properties of the synthesized compounds 
Serial No. Nature of crystals % Yield Melting Point 
0
C 
3a Light yellow crystals 85 137-138 
3b Yellow crystals 95 152-153 
3c Yellow crystals 96 201-202 
3d Yellow crystals 85 135-136 
3e Light yellow crystals 96 177-178 
3f Yellow crystals 80 142-143 
3g Orange crystals 95 160-161 
3h Light yellow crystals 96 150-151 
3i Light yellow crystals 98 175-176 
3j Yellow crystals 98 220-221 
3k Light yellow crystals 85 204-205 
3.1.3 Spectroscopic data 
3.1.3.1 Characterization by 13CNMR and 1H NMR 
The dihydropyrimidine which is the pharmacophore of the structure was identified in all 
compounds with NH-proton resonating around δH 7.3–8.0 as a singlet.  The aromatic 
hydrogen appeared around δH7.0-7.8, while the methine proton signalsobserved as multiplet 
in the 
1
H NMR, appeared around δH 5.30-5.91.  The multipletsignal around δH 4.00-4.15was 
attributed to CH2protons. The CH3 (methyl) protons of the pyramidine ring resonatedas a 
singlet around δH1.14-2.50. 
In
13
C NMR, the C=S aromatic carbon peak was observed around δ145.88-176.00 and 
heterocyclic carbons were found just down filed of the solvent peak around δ 100.00-160.00.  
The methine and methyl carbon signalsappeared slightly up filed of the solvent peak 
betweenδ 60.0 and 13.0.The structures of synthesized compounds were established on the 
basis of their spectral analytical data (FT-IR, 
1
H NMR, and 
13
C NMR) as shown below. 
 
 








Molecular Formula: C14H15ClN2O2S Formula weight:310.80gmol
-1
 





): 3173.73(N-H), 1706.51(C=O), 1651.31(C=C), 726.19 (C-H) 
1
H NMR (400MHz, CDCl3): δ8.29 (s,1H,NH), 7.40-7.38 (m,1H,Ar-H), 7.34 (s,1H,NH), 
7.27-7.22 (m,3H,Ar-H), 5.91-5.90 (m,1H,CH), 4.05-4.00 (q,2H,CH2), 2.46 (s,3H,CH3 of 
pyrimidine ring), 1.08-1.05 (t,3H,CH3) ppm. 
13
C NMR(100MHz, CDCl3):δ174.35 (C=S), 164.85 (C=O), 144.50-100.70 (Aromatic and 
Heterocyclic carbons), 60.37 (methine carbon), 52.68 (O-CH2), 18.01 (C-4 of pyrimidine 










Molecular Formula:C14H15FN2O2S Formula weight:294.34gmol
-1
 





): 3178.05 (N-H), 1706.77 (C=O), 1650.29 (C=C), 755.44(C-H). 
1
H NMR (400MHz, CDCl3, δ):8.53 (s,1H,NH), 7.42-7.03 (m,4H,Ar-H), 7.51(s,1H,NH), 5.73 
(s,1H,CH), 4.08-4.03 (q,2H,CH2), 2.42 (s,3H,CH3 of pyrimidine ring), 1.11 (t,3H,CH3) ppm. 
13
C NMR (100MHz, CDCl3, δ):174.46 (C=S), 164.92 (C=O), 161.30-100.42 (Aromatic and 
heterocyclic carbons), 60.36 (C-4 of pyrimidine ring), 49.96 (O-CH2), 18.06 (CH3), 13.88 













Molecular Formula:C16H20N2O4S  Formula weight: 336.41gmol
-1
 





): 3305.40 (N-H), 1658.77 (C=O), 1573.76 (C=C), 762.30 (C-H) 
1
H NMR (400MHz , CDCl3, δ): 8.37(s,1H,NH), 7.80 (s, 1H, NH), 6.80-6.78 (m,3H,Ar-H), 
5.33 (s,1H,CH), 4.10-4.05(q,2H,CH2), 3.82 (s,6H,OCH3), 2.33 (s,3H,CH3 of pyrimidine ring), 
1.17-1.14 (t,3H,CH3) ppm. 
13
C NMR (100MHz, CDCl3, δ): 174.16 (C=S), 165.35(C=O), 148.99-102.95(Aromatic and 
heterocyclic carbons), 60.36(C-4 of pyrimidine ring), 55.87-55.65(O-CH3), 18.15 (CH3), 










Molecular Formula:C14H15ClN2O2S Formula weight:310.80gmol
-1
 
Physical description:Yellow crystal; Melting point: 202
0
C;Yield: 96% (0.9763g) 
IR (υmax, cm
-1
): 3309.86(N-H), 1661.07 (C=O), 1566.86 (C=C), 744.35(C-H) 
1
H NMR (400MHz, CDCl3, δ): 8.07(s,1H,NH), 7.55(s,1H,NH); 7.26-7.16(m,4H,Ar-H), 5.37 
(s,1H,CH),4.12-4.07 (q,2H,CH2), 2.36 (s, 3H, CH3 of pyrimidine ring), 1.20-1.16 (t, 3H, CH3) 
ppm. 
 




C NMR(100MHz, CDCl3, δ):174.84(C=S), 164.93(C=O), 144.17-102.42 (Aromatic and 
heterocyclic), 60.61 (C-4 of pyrimidine ring), 55.85(O-CH2), 18.57 (CH3), 










Molecular Formula:C16H20N2O4S  Formula weight:336.41gmol
-1
 





):3176.27(N-H), 1682.59(C=O), 1583.65(C=C), 740.47(C-H) 
1
H NMR (400MHz, CDCl3, δ): 7.62(s, 1H, NH), 7.09(s, 1H, NH), 6.86-6.76(m,3H,Ar-H), 
5.68 (s,1H,OH), 5.32-5.31(m,1H,CH), 4.13-4.05(q,2H,CH2), 2.34 (s,3H,CH3 of  pyrimidine 
ring), 2.16(s,2H,CH2), 1.45-1.41 (t,3H,CH3), 1.20-1.16 (t, 3H, CH3) ppm.  
13
C NMR (100MHz, CDCl3, δ): 145.99-145.88(C=S), 141.92(C=O), 134.41(C=O), 119.69-
103.27(Aromatic and heterocyclic carbons), 64.5(C-4 of pyrimidine ring), 60.45 (OCH2), 








Molecular Formula:C15H18N2O3S  Formula weight:306.10g/mol
-1
 





):3294.9(N-H), 1657.8 (C=O), 1570.5(C=C), 699.6(C-H) 
1
H NMR (400MHz , CDCl3, δ):8.088(s,1H,NH), 7.41(s,1H,NH), 7.26-6.80(m,4H,Ar-H), 
5.37(s,1H,CH),4.11-4.06(q,2H,CH2),3.77(s,3H,OCH3), 2.351(s,3H,CH3 of pyrimidine), 1.19-
1.15(t,3H,CH3) ppm. 




C NMR(100MHz, CDCl3, δ):174.63(C=S), 165.21(C=O), 143.76-102.72 (Aromatic and 
heterocyclic carbons), 60.42 (C-4 of pyrimidine ring), 56.04(O-CH2), 55.23(O-CH3), 18.33 









Molecular Formula:C14H15ClN2O2S Formula weight:310.80 gmol
-1
 
Physical description: Yellow Crystals; Meltingpoint:178
0
C; Yield:96% (0.9735g) 
IR (υmax, cm
-1
):3325.59(N-H), 1668.50(C=O), 1572.52(C=C),744.89(C-H)  
1
H NMR (400MHz, CDCl3, δ):8.31(s,1H,NH),7.82(s,1H,NH), 7.30- 7.21(m,4H,Ar-H), 
5.38(s,1H,CH), 4.13-4.07(q,2H,CH2), 2.36(s,3H,CH3 of pyrimidine ring), 1.20-1.17 
(t,3H,CH3) ppm. 
13
C NMR(100MHz, CDCl3, δ): 174.39(C=S), 165.08(C=O), 143.05-102.61(Aromatic and 
heterocyclic carbons),60.55(C-4 of pyrimidine ring), 55.40(O-CH2), 18.29(CH3), 14.08(CH3). 










Molecular Formula:C15H18N2O3S  Formula weight:306.10gmol
-1
 





):3310.02(N-H), 1664.94(C=O), 1573.31(C=C), 764.60(C-H) 




H NMR (400MHz, CDCl3, δ): 8.20(s,1H,NH), 7.56(s,1H,NH),  7.26-6.81(m,4H,Ar-H), 
5.33(s,1H,CH), 4.09-4.05(q,2H,CH2),3.77(s,3H, OCH3),2.34(s, 3H, CH3of pyrimidine ring), 
1.18-1.14(t, 3H, CH3) ppm. 
13
C NMR(100MHz, CDCl3, δ):174.19(C=S), 165.28(C=O), 59.52-103.14(Aromatic and 
heterocyclic carbons), 60.36(C-4 of pyrimidine ring),55.59-55.25(OCH3), 18.22(CH3), 











Molecular Formula:C15H18N2O2S  Formula weight:290.38gmol
-1
 
Physical description:Yellow Crystals; Melting point: 176
0
C; Yield:98% (0.9912g) 
IR(υmax, cm
-1
):3321.40(N-H), 1669.72(C=O), 1573.95(C=C), 758.80(C-H) 
1
H NMR (400 MHz, CDCl3, δ): 8.33(s, 1H, NH), 7.67(s, 1H, NH), 7.26-7.09 
(m, 4H, Ar-H), 5.34(s, 1H,CH), 4.10-4.04(q,2H,CH2), 2.33-2.30(s,3H,CH3 of pyrimidine 
ring), 2.163(s,1H,CH3), 1.18-1.4 (t,3H,CH3)ppm. 
13
C NMR(100MHz, CDCl3, δ):174.26(C=S), 165.29(C=O),142.79-102.99 (Aromatic and 
heterocyclic carbons), 60.35 (C-4 of pyrimidine ring), 55(OCH2), 21.09(CH3), 18.17(CH3), 









Molecular Formula:C14H16N2O2S  Formula weight:276.35gmol
-1
 
Physical description:Yellow Crystals;Melting point:204
0
C; Yield:85% (0.8632g) 





):3324.36(N-H), 1666.27(C=O), 1573.06(C=C), 758.66(C-H) 
1
H NMR (400MHz , CDCl3, δ): 8.02(s,1H,NH), 7.401(s,1H,NH), 7.34-7.26(m,4H,Ar-H), 
5.397(s,1H,CH), 4.11-4.05(q,2H,CH2), 2.35(s,3H,CH3 of pyrimidine ring), 1.17-
1.14(t,3H,CH3) ppm. 
13
C NMR(100MHz, CDCl3, δ): 174.57(C=S), 165.20(C=O), 142.64-102.93(Aromatic and 
heterocyclic carbon), 60.42(C-4 of pyrimidine ring), 56.22(OCH2), 18.34(CH3), 14.05(CH3). 









Molecular Formula:C12H20N2O2S  Formula weight:256.36 gmol
-1
 





): 3175.66(N-H), 1708.75(C=O), 1593.79(C=C), 746.89(C-H) 
1
H NMR (400 MHz, CDCl3, δ):8.18(s,1H,NH), 7.68(s,1H,NH), 4.34(s,1H,CH), 4.14-
4.11(q,2H,CH2), 2.28(s,3H,CH3 of pyrimidine ring), 1.60-1.54(m,7H), 1.521-1.46 (d,3H,CH3) 
ppm. 
13
C NMR (100MHz, CDCl3, δ): 175.48(C=S), 165.48(C=O), 143.60(C-6 of pyrimidine ring), 
103.02(C-5 of pyrimidine ring), 60.34 (C-4 of pyrimidine ring), 52.27(OCH2), 36.29-22.30 





3.1.4 Interpretation of spectral analysis 
3.1.4.1 Infra-red spectroscopy  
Different functional groups of synthesised compounds were determined using Infra-red 
spectroscopy.  The presence of the characteristic band around 3100-3300cm
-1
show the 
presence of (N-H stretches) of primary amines in compounds 3a-3kas shown in Figure 32. 
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Figure 32.IR spectra of compound 3g 
3.1.4.2 1H NMR spectroscopy  
From
1
H NMRspectra of compounds 3a-3k, it showed that the most prominent singlet signal 
appeared around δ 7.8 ppm and δ 8.37 ppm. It was attributed to two (NH) protons while one 
distinctive multiplet signal around δ 6.80-6.78ppm were assigned to aromatic protons as 
depicted on Figure 33. 
 




H NMR spectroscopy of compound
3.1.4.3 13C NMR spectroscopy  
In 
13
C NMR spectrum of compounds 
δ165.3ppm confirmed the presence of carbonyl carbon (C=O). Methoxy carbons   resonated 














3.2 Invitro biological assay  
The synthesized dihydropyrimidinones were evaluated for their minimum inhibitory 
concentration (MIC) by broth dilution method against bacterial 
ATCC25923, B. subtilisATCC6051,
fungal C. albicans ATCC90028, 
Durban.  In general these compounds were found to be less effective against tested bacterial 
strains. All the tested compounds were in
ATCC25923 and Gram-negative 
µg/mL).  Compound 2 with para
active compound against B. subtilis
that substitution of electron donating methoxy
favorable for activity toward 
substituent at phenyl ring was fou
ATCC27853. This revealed that substitution of electron donating methyl
position is more favored than other substations for activity towards 
 
of compound 3g 
Staphyloccocusaureus
 E. coli ATCC35218, P. aeruginosa ATCC27853 and 
C. neoformans ATCC66031 at Albert Luthuli Hospital, 
active towards Gram-Positive Staphyloccocusaureus
E. coli ATCC35218 at the tested concentration (200 
-methoxy substituent on phenyl ring was found to be most 
ATCC6051 with MIC value of 100 µg/mL. This indicated 
- substitution at para-position of phenyl ring is 
B. subtilisATCC6051. Compound 1 with para
nd to be most active against Gram-negative P. aeruginosa 
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ATCC27853. Standard Moxicillin showed highly potent activity (MIC = <0.39 
µg/mL)towards all tested bacterial strains. 









1 >200 200 200 100 
2 >200 100 200 200 
3 >200 200 >200 >200 
4 >200 >200 >200 >200 
5 200 >200 200 >200 
6 
>200 
200 200 >200 
7 
>200 
200 200 >200 
8 
>200 
>200 200 >200 
9 
>200 
>200 200 >200 
10 
>200 
>200 200 200 
11 200 200 200 200 
Moxycillin <0.39 <0.39 <0.39 <0.39 
The synthesized dihydropyrimidinones were also evaluated for their minimum inhibitory 
concentration (MIC) by broth dilution method against fungal C. albicans ATCC90028, C. 
neoformans ATCC66031 at Albert Luthuli Hospital, Durban.  In general these compounds 
were found to be less effective against tested fungal strains.  All the tested compounds were 
inactive towards tested fungal strains (MIC = >200 µg/mL).  Standard Amphotericin B 
showed highly potent activity towards C. albicans ATCC90028and C. neoformans 
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1 200 >200 
2 200 >200 
3 200 >200 
4 200 >200 
5 200 >200 
6 200 >200 
7 200 >200 
8 200 >200 
9 200 >200 
10 200 >200 
11 200 >200 
Amphotericin B 0.25 1-2 
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CONCLUSION AND  
FUTURE WORK 
 




4 Conclusion and Future Work  
Conclusively, a series of 1,2,3,4-tetrahydropyrimidine 3(a-k) have been successfully 
synthesized, characterized and evaluated for their antibacterial and antifungal activity. In 
general these compounds were found to be less effective against tested bacterial strains. All 
the tested compounds were inactive towards Gram-Positive Staphyloccocusaureus 
ATCC25923 and Gram-negative E. coli ATCC35218 at the tested concentration (200 
µg/mL).  Compound 2 with para-methoxy substituent on phenyl ring was found to be 
moderately active against B. subtilis ATCC6051 with MIC value of 100 µg/mL.  This 
indicated that substitution of electron donating methoxy- substitution at para-position of 
phenyl ring is favorable for activity toward B. subtilisATCC6051 and no compound was 
found to be active against fungal strain. 
Possible improvements in the antimicrobial activity can be further achieved by slight 
modifications in the substituent’s and/or additional structural activity investigations to have 















































































































































































































































































































































































































































































































































































































































































Spectrum 33. IR of compound 3k 
